Wiener klinische Wochenschrift

, Volume 126, Issue 3–4, pp 79–89

Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013

  • Judith Sautner
  • Johann Gruber
  • Manfred Herold
  • Jochen Zwerina
  • Burkhard F. Leeb
originalarbeit

Zusammenfassung

Grundlagen

Gicht ist die häufigste entzündliche Gelenkerkrankung in der westlichen Welt und zeigt eine steigende Prävalenz. Nach dem Vorbild früherer 3e-Empfehlungen (Evidence-Expertise-Exchange) zu anderen rheumatologischen Problemen war das jetzige Ziel die Erstellung von internationalen Empfehlungen zur Diagnose und Therapie von Gicht und Hyperuricämie auf Basis einer systematischen Literatursuche.

Methodik

Zu Beginn des 3e-Projektes wurden in den teilnehmenden Ländern in einem Delphi-Prozess zunächst jeweils 10 nationale Fragen erstellt, die dann zu 10 internationalen Fragen verknüpft wurden. Danach wurde eine systematische Literatursuche durchgeführt. Auf Basis dieser Literatur wurden in einem nächsten Schritt wieder zunächst nationale und in weiterer Folge daraus internationale Empfehlungen formuliert. Der Grad der Zustimmung wurde dokumentiert und die Antworten nach Evidenzgrad klassifiziert.

Ergebnisse

Ein österreichisches Expertengremium erstellte unter Zuhilfenahme der verfügbaren Literatur 10 Empfehlungen zu Diagnostik und Therapie der Gicht bzw. Hyperuricämie.

Nach Publikation der internationalen 3e-Empfehlungen präsentieren wir hier einen Überblick über die nationalen österreichischen Fragen und Experten-Empfehlungen zu Diagnostik und Therapie der Gicht 2013 sowie einen Vergleich der österreichischen mit den internationalen Empfehlungen.

Schlüsselwörter

Gicht Hyperuricämie Empfehlungen Diagnose Therapie 

Austrian 3e-recommendations for diagnosis and management of gout 2013

Summary

Background

Gout is the most common inflammatory joint disease in the Western world, with increasing prevalence. Like former 3e-initiatives (Experts-Evidence-Education) dealing with other rheumatological problems, this initiative aimed at the development of international recommendations for the diagnosis and management of gout and hyperuricemia based on a systematic literature research.

Methods

In the participating countries 10 national questions were generated via a Delphi-process. These questions were collected and out of this pool 10 international questions were formulated. Afterwards a systematic literature research was performed. On that basis again first national and afterwards international recommendations were generated.

Results

On the basis of the available literature an Austrian expert panel developed 10 recommendations on diagnosis and management of gout and hyperuricemia.

After publication of the international 3e-recommendations we hereby present the national Austrian questions and expert-recommendations for diagnosis and management of gout 2013 followed by a comparison of the Austrian and the international recommendations.

Keywords

Gout Hyperuricemia Recommendations Diagnosis Management 

Literatur

  1. 1.
    Li C, Hsieh MC, Chang SJ. Metabo lic syndrome, diabetes, and hyperuricemia. Curr Opin. Rheumatol. 2013 Mar;25(2):210–6.Google Scholar
  2. 2.
    Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811–21.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109(4):486–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–11.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 ACR guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012 Oct;64(19):1431–46.CrossRefGoogle Scholar
  7. 7.
    Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 ACR guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2021 Oct;64(19):1447–61.CrossRefGoogle Scholar
  8. 8.
    Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013–203325.Google Scholar
  9. 9.
    Janssens HJ, Janssen M, van den Lisdonk EH, et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis. 2010;69:1255–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Lai KL, Chiu YM. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13.CrossRefGoogle Scholar
  13. 13.
    Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010 Oct;123(10):957–61.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006 Aug;187(2):401–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006 Jun;37(6):1503–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010 Jan;49(1):141–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013 Jan;52(1):127–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Strasak AM, Rapp K, Hilbe W, et al. VHM & PP Study Group. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol. 2007 Nov;18(11):1893–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb;169(4):342–50.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Janssens HJ, Jannse M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: 24h outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology. 2007;46(7):1126–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Choi HK, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093–103PubMedCrossRefGoogle Scholar
  24. 24.
    Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309–12.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 69(9):1677–82.Google Scholar
  26. 26.
    Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficay and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):63.Google Scholar
  27. 27.
    Singh JA;Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429–32.PubMedGoogle Scholar
  29. 29.
    Paulus HE, Schlosstein LH Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo controlled study od probenecid-treated pateints. Arthritis Rheum. 1974;17(5):609–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Schlesinger N, Mysler E, Lin HY, et al. Cnakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11(2):104–7.Google Scholar
  32. 32.
    Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Ohue T, Yamamoto T, et al. Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients. Japanese J Rheumatology. 1991;3(1):21–7.Google Scholar
  34. 34.
    De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind- randomized study. Eur Rev Med Pharmacol Sci. 2007;11:179–84.Google Scholar
  35. 35.
    Jordan KM, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Rheumatology. 2007;26:1372–74.CrossRefGoogle Scholar
  36. 36.
    Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786–90.PubMedCrossRefGoogle Scholar
  37. 37.
    Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–25.Google Scholar
  38. 38.
    Dalbeth N, McQueen FM, Singh JA, et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities. J Rheumatol. 2011;38(7):1458–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888–93.PubMedGoogle Scholar
  40. 40.
    Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–45.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Taylor WJ, Colvine K, Gregory K, et al. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620–26.PubMedGoogle Scholar
  42. 42.
    Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase fort he treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophy in chronic gout. Arthritis Rheum. 2002;47(4):356–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Siu YP, Leung KT, Tong MK and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan:47(1):51–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349–55.PubMedCrossRefGoogle Scholar
  50. 50.
    Haindl PM, Rintelen B, Brezinschek HP, et al. Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen Literatursuche. Akt Rheumatol. 2010;35:251–9.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Judith Sautner
    • 1
  • Johann Gruber
    • 2
  • Manfred Herold
    • 2
  • Jochen Zwerina
    • 3
  • Burkhard F. Leeb
    • 1
  1. 1.State Hospital Stockerau, 2nd Medical Department,Lower Austrian Centre for RheumatologyKarl Landsteiner Institute for Clin. RheumatologyStockerauÖsterreich
  2. 2.Department of RheumatologyMed. University of Innsbruck VIInnsbruckÖsterreich
  3. 3.Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling,1st Medical DepartmentHanusch HospitalWienÖsterreich

Personalised recommendations